These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 21118058)
1. Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity. Leishman AJ; Sims GP; Sleeman M; Braddock M Expert Opin Investig Drugs; 2011 Jan; 20(1):23-39. PubMed ID: 21118058 [TBL] [Abstract][Full Text] [Related]
2. Drug delivery technologies for autoimmune disease. Phillips BE; Giannoukakis N Expert Opin Drug Deliv; 2010 Nov; 7(11):1279-89. PubMed ID: 20958218 [TBL] [Abstract][Full Text] [Related]
3. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Williams RO; Paleolog E; Feldmann M Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887 [TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
5. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Van Kaer L Nat Rev Immunol; 2005 Jan; 5(1):31-42. PubMed ID: 15630427 [TBL] [Abstract][Full Text] [Related]
6. Possible molecular mechanisms to account for the efficacy of allopurinol against experimental autoimmune uveitis. Namazi MR Int Immunopharmacol; 2004 Jan; 4(1):161-2. PubMed ID: 14975372 [No Abstract] [Full Text] [Related]
7. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Hu Y; Shen F; Crellin NK; Ouyang W Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836 [TBL] [Abstract][Full Text] [Related]
8. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. Perosa F; Prete M; Racanelli V; Dammacco F J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920 [TBL] [Abstract][Full Text] [Related]
9. Targeting T regulatory cells in autoimmune diseases. Toubi E Isr Med Assoc J; 2008 Jan; 10(1):73-6. PubMed ID: 18300580 [TBL] [Abstract][Full Text] [Related]
10. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Ghoneum M; Jewett A Cancer Detect Prev; 2000; 24(4):314-24. PubMed ID: 11059563 [TBL] [Abstract][Full Text] [Related]
13. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Cope AP; Feldmann M Curr Opin Immunol; 2004 Dec; 16(6):780-6. PubMed ID: 15511673 [TBL] [Abstract][Full Text] [Related]
14. Setting the cytokine trap for autoimmunity. Dinarello CA Nat Med; 2003 Jan; 9(1):20-2. PubMed ID: 12514715 [No Abstract] [Full Text] [Related]
15. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Ranheim EA; Kipps TJ Cell Immunol; 1995 Apr; 161(2):226-35. PubMed ID: 7535196 [TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells and autoimmunity. Vila J; Isaacs JD; Anderson AE Curr Opin Hematol; 2009 Jul; 16(4):274-9. PubMed ID: 19417650 [TBL] [Abstract][Full Text] [Related]
17. [The future of antibody fragments, made of a single immunoglobulin domain]. Chames P; Baty D Med Sci (Paris); 2009 Dec; 25(12):1159-62. PubMed ID: 20035698 [TBL] [Abstract][Full Text] [Related]
18. Understanding autoimmune disease: new targets for drug discovery. Balagué C; Kunkel SL; Godessart N Drug Discov Today; 2009 Oct; 14(19-20):926-34. PubMed ID: 19596080 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-17 as a drug target in human disease. Ivanov S; Lindén A Trends Pharmacol Sci; 2009 Feb; 30(2):95-103. PubMed ID: 19162337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]